nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—CYP1A2—Pentoxifylline—systemic scleroderma	0.087	0.217	CbGbCtD
Alitretinoin—CYP1A2—Leflunomide—systemic scleroderma	0.083	0.207	CbGbCtD
Alitretinoin—ABCB1—Lisinopril—systemic scleroderma	0.0761	0.189	CbGbCtD
Alitretinoin—ABCB1—Captopril—systemic scleroderma	0.057	0.142	CbGbCtD
Alitretinoin—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0448	0.112	CbGbCtD
Alitretinoin—ABCB1—Prednisone—systemic scleroderma	0.0358	0.0892	CbGbCtD
Alitretinoin—ABCB1—Methotrexate—systemic scleroderma	0.018	0.0448	CbGbCtD
Alitretinoin—CRABP1—connective tissue—systemic scleroderma	0.00611	0.0774	CbGeAlD
Alitretinoin—CRABP2—connective tissue—systemic scleroderma	0.00552	0.07	CbGeAlD
Alitretinoin—CRABP1—skin of body—systemic scleroderma	0.00551	0.0699	CbGeAlD
Alitretinoin—CRABP2—smooth muscle tissue—systemic scleroderma	0.00505	0.064	CbGeAlD
Alitretinoin—CRABP2—skin of body—systemic scleroderma	0.00499	0.0632	CbGeAlD
Alitretinoin—CRABP1—tendon—systemic scleroderma	0.0042	0.0532	CbGeAlD
Alitretinoin—CRABP2—digestive system—systemic scleroderma	0.00399	0.0505	CbGeAlD
Alitretinoin—CRABP2—tendon—systemic scleroderma	0.0038	0.0481	CbGeAlD
Alitretinoin—RARG—skin of body—systemic scleroderma	0.00364	0.0461	CbGeAlD
Alitretinoin—RARB—tendon—systemic scleroderma	0.0034	0.043	CbGeAlD
Alitretinoin—CRABP2—lung—systemic scleroderma	0.00333	0.0422	CbGeAlD
Alitretinoin—RXRG—tendon—systemic scleroderma	0.00332	0.042	CbGeAlD
Alitretinoin—RXRB—tendon—systemic scleroderma	0.00312	0.0395	CbGeAlD
Alitretinoin—RARB—lung—systemic scleroderma	0.00298	0.0378	CbGeAlD
Alitretinoin—RARG—digestive system—systemic scleroderma	0.00291	0.0369	CbGeAlD
Alitretinoin—RARG—tendon—systemic scleroderma	0.00277	0.0351	CbGeAlD
Alitretinoin—RXRB—lung—systemic scleroderma	0.00274	0.0347	CbGeAlD
Alitretinoin—RARA—tendon—systemic scleroderma	0.0026	0.033	CbGeAlD
Alitretinoin—RARG—lung—systemic scleroderma	0.00243	0.0308	CbGeAlD
Alitretinoin—RARA—lung—systemic scleroderma	0.00229	0.029	CbGeAlD
Alitretinoin—ABCB1—blood vessel—systemic scleroderma	0.0014	0.0178	CbGeAlD
Alitretinoin—CYP1A2—digestive system—systemic scleroderma	0.00101	0.0129	CbGeAlD
Alitretinoin—CYP1A2—lung—systemic scleroderma	0.000847	0.0107	CbGeAlD
Alitretinoin—ABCB1—digestive system—systemic scleroderma	0.00052	0.00659	CbGeAlD
Alitretinoin—ABCB1—lung—systemic scleroderma	0.000434	0.0055	CbGeAlD
Alitretinoin—Abdominal pain—Leflunomide—systemic scleroderma	0.000176	0.000339	CcSEcCtD
Alitretinoin—Body temperature increased—Leflunomide—systemic scleroderma	0.000176	0.000339	CcSEcCtD
Alitretinoin—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000175	0.000338	CcSEcCtD
Alitretinoin—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000175	0.000337	CcSEcCtD
Alitretinoin—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000336	CcSEcCtD
Alitretinoin—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000336	CcSEcCtD
Alitretinoin—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000336	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000174	0.000336	CcSEcCtD
Alitretinoin—Myocardial infarction—Prednisone—systemic scleroderma	0.000174	0.000336	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000174	0.000335	CcSEcCtD
Alitretinoin—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000174	0.000335	CcSEcCtD
Alitretinoin—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000174	0.000335	CcSEcCtD
Alitretinoin—Hypersensitivity—Azathioprine—systemic scleroderma	0.000174	0.000334	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000174	0.000334	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000174	0.000334	CcSEcCtD
Alitretinoin—Insomnia—Lisinopril—systemic scleroderma	0.000173	0.000333	CcSEcCtD
Alitretinoin—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000173	0.000332	CcSEcCtD
Alitretinoin—Paraesthesia—Lisinopril—systemic scleroderma	0.000172	0.00033	CcSEcCtD
Alitretinoin—Vomiting—Captopril—systemic scleroderma	0.000172	0.00033	CcSEcCtD
Alitretinoin—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000171	0.000329	CcSEcCtD
Alitretinoin—Dyspnoea—Lisinopril—systemic scleroderma	0.00017	0.000328	CcSEcCtD
Alitretinoin—Rash—Captopril—systemic scleroderma	0.00017	0.000328	CcSEcCtD
Alitretinoin—Dermatitis—Captopril—systemic scleroderma	0.00017	0.000327	CcSEcCtD
Alitretinoin—Somnolence—Lisinopril—systemic scleroderma	0.00017	0.000327	CcSEcCtD
Alitretinoin—Headache—Captopril—systemic scleroderma	0.000169	0.000326	CcSEcCtD
Alitretinoin—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000169	0.000325	CcSEcCtD
Alitretinoin—Dyspepsia—Lisinopril—systemic scleroderma	0.000168	0.000324	CcSEcCtD
Alitretinoin—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000168	0.000323	CcSEcCtD
Alitretinoin—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000168	0.000323	CcSEcCtD
Alitretinoin—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000322	CcSEcCtD
Alitretinoin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000322	CcSEcCtD
Alitretinoin—Asthma—Methotrexate—systemic scleroderma	0.000167	0.000321	CcSEcCtD
Alitretinoin—Infection—Mycophenolate mofetil—systemic scleroderma	0.000166	0.00032	CcSEcCtD
Alitretinoin—Decreased appetite—Lisinopril—systemic scleroderma	0.000166	0.00032	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000165	0.000318	CcSEcCtD
Alitretinoin—Fatigue—Lisinopril—systemic scleroderma	0.000165	0.000317	CcSEcCtD
Alitretinoin—Shock—Mycophenolate mofetil—systemic scleroderma	0.000165	0.000317	CcSEcCtD
Alitretinoin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000164	0.000316	CcSEcCtD
Alitretinoin—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000164	0.000316	CcSEcCtD
Alitretinoin—Hypersensitivity—Leflunomide—systemic scleroderma	0.000164	0.000316	CcSEcCtD
Alitretinoin—Pancreatitis—Methotrexate—systemic scleroderma	0.000164	0.000315	CcSEcCtD
Alitretinoin—Pain—Lisinopril—systemic scleroderma	0.000163	0.000315	CcSEcCtD
Alitretinoin—Constipation—Lisinopril—systemic scleroderma	0.000163	0.000315	CcSEcCtD
Alitretinoin—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000163	0.000315	CcSEcCtD
Alitretinoin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000163	0.000313	CcSEcCtD
Alitretinoin—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000162	0.000312	CcSEcCtD
Alitretinoin—Diarrhoea—Azathioprine—systemic scleroderma	0.000161	0.00031	CcSEcCtD
Alitretinoin—Haemoglobin—Prednisone—systemic scleroderma	0.000161	0.000309	CcSEcCtD
Alitretinoin—Nausea—Captopril—systemic scleroderma	0.00016	0.000309	CcSEcCtD
Alitretinoin—Abdominal discomfort—Methotrexate—systemic scleroderma	0.00016	0.000308	CcSEcCtD
Alitretinoin—Haemorrhage—Prednisone—systemic scleroderma	0.00016	0.000308	CcSEcCtD
Alitretinoin—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00016	0.000307	CcSEcCtD
Alitretinoin—Asthenia—Leflunomide—systemic scleroderma	0.00016	0.000307	CcSEcCtD
Alitretinoin—Hallucination—Prednisone—systemic scleroderma	0.000159	0.000306	CcSEcCtD
Alitretinoin—Feeling abnormal—Lisinopril—systemic scleroderma	0.000158	0.000303	CcSEcCtD
Alitretinoin—Pruritus—Leflunomide—systemic scleroderma	0.000157	0.000303	CcSEcCtD
Alitretinoin—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000301	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000156	0.000301	CcSEcCtD
Alitretinoin—Dysuria—Methotrexate—systemic scleroderma	0.000156	0.0003	CcSEcCtD
Alitretinoin—Neutropenia—Methotrexate—systemic scleroderma	0.000156	0.0003	CcSEcCtD
Alitretinoin—Dizziness—Azathioprine—systemic scleroderma	0.000156	0.0003	CcSEcCtD
Alitretinoin—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000155	0.000299	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000153	0.000294	CcSEcCtD
Alitretinoin—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000152	0.000293	CcSEcCtD
Alitretinoin—Asthenia—Mycophenolic acid—systemic scleroderma	0.000152	0.000293	CcSEcCtD
Alitretinoin—Diarrhoea—Leflunomide—systemic scleroderma	0.000152	0.000293	CcSEcCtD
Alitretinoin—Urticaria—Lisinopril—systemic scleroderma	0.000152	0.000292	CcSEcCtD
Alitretinoin—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000151	0.000292	CcSEcCtD
Alitretinoin—Body temperature increased—Lisinopril—systemic scleroderma	0.000151	0.000291	CcSEcCtD
Alitretinoin—Abdominal pain—Lisinopril—systemic scleroderma	0.000151	0.000291	CcSEcCtD
Alitretinoin—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00015	0.00029	CcSEcCtD
Alitretinoin—Pruritus—Mycophenolic acid—systemic scleroderma	0.00015	0.000289	CcSEcCtD
Alitretinoin—Vomiting—Azathioprine—systemic scleroderma	0.00015	0.000288	CcSEcCtD
Alitretinoin—Pneumonia—Methotrexate—systemic scleroderma	0.00015	0.000288	CcSEcCtD
Alitretinoin—Eye disorder—Prednisone—systemic scleroderma	0.000149	0.000288	CcSEcCtD
Alitretinoin—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000149	0.000288	CcSEcCtD
Alitretinoin—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000149	0.000287	CcSEcCtD
Alitretinoin—Infestation NOS—Methotrexate—systemic scleroderma	0.000149	0.000286	CcSEcCtD
Alitretinoin—Drowsiness—Methotrexate—systemic scleroderma	0.000149	0.000286	CcSEcCtD
Alitretinoin—Infestation—Methotrexate—systemic scleroderma	0.000149	0.000286	CcSEcCtD
Alitretinoin—Rash—Azathioprine—systemic scleroderma	0.000149	0.000286	CcSEcCtD
Alitretinoin—Dermatitis—Azathioprine—systemic scleroderma	0.000148	0.000286	CcSEcCtD
Alitretinoin—Depression—Methotrexate—systemic scleroderma	0.000148	0.000286	CcSEcCtD
Alitretinoin—Flushing—Prednisone—systemic scleroderma	0.000148	0.000286	CcSEcCtD
Alitretinoin—Headache—Azathioprine—systemic scleroderma	0.000148	0.000284	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000147	0.000284	CcSEcCtD
Alitretinoin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000284	CcSEcCtD
Alitretinoin—Dizziness—Leflunomide—systemic scleroderma	0.000147	0.000283	CcSEcCtD
Alitretinoin—Renal failure—Methotrexate—systemic scleroderma	0.000146	0.000282	CcSEcCtD
Alitretinoin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000146	0.00028	CcSEcCtD
Alitretinoin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000145	0.00028	CcSEcCtD
Alitretinoin—Stomatitis—Methotrexate—systemic scleroderma	0.000145	0.000279	CcSEcCtD
Alitretinoin—Angiopathy—Prednisone—systemic scleroderma	0.000145	0.000279	CcSEcCtD
Alitretinoin—Conjunctivitis—Methotrexate—systemic scleroderma	0.000145	0.000278	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000145	0.000278	CcSEcCtD
Alitretinoin—Pain—Mycophenolate mofetil—systemic scleroderma	0.000143	0.000276	CcSEcCtD
Alitretinoin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000143	0.000276	CcSEcCtD
Alitretinoin—Arrhythmia—Prednisone—systemic scleroderma	0.000143	0.000275	CcSEcCtD
Alitretinoin—Sweating—Methotrexate—systemic scleroderma	0.000143	0.000275	CcSEcCtD
Alitretinoin—Haematuria—Methotrexate—systemic scleroderma	0.000142	0.000273	CcSEcCtD
Alitretinoin—Vomiting—Leflunomide—systemic scleroderma	0.000141	0.000272	CcSEcCtD
Alitretinoin—Alopecia—Prednisone—systemic scleroderma	0.000141	0.000272	CcSEcCtD
Alitretinoin—Hypersensitivity—Lisinopril—systemic scleroderma	0.000141	0.000271	CcSEcCtD
Alitretinoin—Dizziness—Mycophenolic acid—systemic scleroderma	0.00014	0.00027	CcSEcCtD
Alitretinoin—Epistaxis—Methotrexate—systemic scleroderma	0.00014	0.00027	CcSEcCtD
Alitretinoin—Rash—Leflunomide—systemic scleroderma	0.00014	0.00027	CcSEcCtD
Alitretinoin—Dermatitis—Leflunomide—systemic scleroderma	0.00014	0.00027	CcSEcCtD
Alitretinoin—Mental disorder—Prednisone—systemic scleroderma	0.00014	0.00027	CcSEcCtD
Alitretinoin—Nausea—Azathioprine—systemic scleroderma	0.00014	0.000269	CcSEcCtD
Alitretinoin—Headache—Leflunomide—systemic scleroderma	0.000139	0.000268	CcSEcCtD
Alitretinoin—Malnutrition—Prednisone—systemic scleroderma	0.000139	0.000268	CcSEcCtD
Alitretinoin—Erythema—Prednisone—systemic scleroderma	0.000139	0.000268	CcSEcCtD
Alitretinoin—Agranulocytosis—Methotrexate—systemic scleroderma	0.000139	0.000267	CcSEcCtD
Alitretinoin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000266	CcSEcCtD
Alitretinoin—Asthenia—Lisinopril—systemic scleroderma	0.000137	0.000264	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000137	0.000264	CcSEcCtD
Alitretinoin—Pruritus—Lisinopril—systemic scleroderma	0.000135	0.00026	CcSEcCtD
Alitretinoin—Vomiting—Mycophenolic acid—systemic scleroderma	0.000135	0.00026	CcSEcCtD
Alitretinoin—Haemoglobin—Methotrexate—systemic scleroderma	0.000134	0.000258	CcSEcCtD
Alitretinoin—Rash—Mycophenolic acid—systemic scleroderma	0.000134	0.000258	CcSEcCtD
Alitretinoin—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000134	0.000257	CcSEcCtD
Alitretinoin—Haemorrhage—Methotrexate—systemic scleroderma	0.000134	0.000257	CcSEcCtD
Alitretinoin—Hepatitis—Methotrexate—systemic scleroderma	0.000134	0.000257	CcSEcCtD
Alitretinoin—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000133	0.000256	CcSEcCtD
Alitretinoin—Headache—Mycophenolic acid—systemic scleroderma	0.000133	0.000256	CcSEcCtD
Alitretinoin—Pharyngitis—Methotrexate—systemic scleroderma	0.000133	0.000255	CcSEcCtD
Alitretinoin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000132	0.000255	CcSEcCtD
Alitretinoin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000132	0.000255	CcSEcCtD
Alitretinoin—Nausea—Leflunomide—systemic scleroderma	0.000132	0.000254	CcSEcCtD
Alitretinoin—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000132	0.000254	CcSEcCtD
Alitretinoin—Vision blurred—Prednisone—systemic scleroderma	0.000131	0.000252	CcSEcCtD
Alitretinoin—Urethral disorder—Methotrexate—systemic scleroderma	0.000131	0.000252	CcSEcCtD
Alitretinoin—Diarrhoea—Lisinopril—systemic scleroderma	0.000131	0.000252	CcSEcCtD
Alitretinoin—Ill-defined disorder—Prednisone—systemic scleroderma	0.000129	0.000249	CcSEcCtD
Alitretinoin—Visual impairment—Methotrexate—systemic scleroderma	0.000129	0.000248	CcSEcCtD
Alitretinoin—Anaemia—Prednisone—systemic scleroderma	0.000129	0.000248	CcSEcCtD
Alitretinoin—Agitation—Prednisone—systemic scleroderma	0.000128	0.000246	CcSEcCtD
Alitretinoin—Dizziness—Lisinopril—systemic scleroderma	0.000126	0.000243	CcSEcCtD
Alitretinoin—Erythema multiforme—Methotrexate—systemic scleroderma	0.000126	0.000243	CcSEcCtD
Alitretinoin—Nausea—Mycophenolic acid—systemic scleroderma	0.000126	0.000243	CcSEcCtD
Alitretinoin—Malaise—Prednisone—systemic scleroderma	0.000125	0.000242	CcSEcCtD
Alitretinoin—Eye disorder—Methotrexate—systemic scleroderma	0.000125	0.00024	CcSEcCtD
Alitretinoin—Syncope—Prednisone—systemic scleroderma	0.000125	0.00024	CcSEcCtD
Alitretinoin—Tinnitus—Methotrexate—systemic scleroderma	0.000125	0.00024	CcSEcCtD
Alitretinoin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000123	0.000238	CcSEcCtD
Alitretinoin—Loss of consciousness—Prednisone—systemic scleroderma	0.000122	0.000235	CcSEcCtD
Alitretinoin—Vomiting—Lisinopril—systemic scleroderma	0.000122	0.000234	CcSEcCtD
Alitretinoin—Angiopathy—Methotrexate—systemic scleroderma	0.000121	0.000233	CcSEcCtD
Alitretinoin—Rash—Lisinopril—systemic scleroderma	0.000121	0.000232	CcSEcCtD
Alitretinoin—Convulsion—Prednisone—systemic scleroderma	0.000121	0.000232	CcSEcCtD
Alitretinoin—Dermatitis—Lisinopril—systemic scleroderma	0.00012	0.000232	CcSEcCtD
Alitretinoin—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000231	CcSEcCtD
Alitretinoin—Hypertension—Prednisone—systemic scleroderma	0.00012	0.000231	CcSEcCtD
Alitretinoin—Chills—Methotrexate—systemic scleroderma	0.00012	0.000231	CcSEcCtD
Alitretinoin—Headache—Lisinopril—systemic scleroderma	0.00012	0.000231	CcSEcCtD
Alitretinoin—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000228	CcSEcCtD
Alitretinoin—Myalgia—Prednisone—systemic scleroderma	0.000118	0.000228	CcSEcCtD
Alitretinoin—Arthralgia—Prednisone—systemic scleroderma	0.000118	0.000228	CcSEcCtD
Alitretinoin—Anxiety—Prednisone—systemic scleroderma	0.000118	0.000227	CcSEcCtD
Alitretinoin—Alopecia—Methotrexate—systemic scleroderma	0.000118	0.000227	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000118	0.000226	CcSEcCtD
Alitretinoin—Discomfort—Prednisone—systemic scleroderma	0.000117	0.000225	CcSEcCtD
Alitretinoin—Mental disorder—Methotrexate—systemic scleroderma	0.000117	0.000225	CcSEcCtD
Alitretinoin—Erythema—Methotrexate—systemic scleroderma	0.000116	0.000224	CcSEcCtD
Alitretinoin—Malnutrition—Methotrexate—systemic scleroderma	0.000116	0.000224	CcSEcCtD
Alitretinoin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000221	CcSEcCtD
Alitretinoin—Nausea—Lisinopril—systemic scleroderma	0.000114	0.000219	CcSEcCtD
Alitretinoin—Oedema—Prednisone—systemic scleroderma	0.000114	0.000219	CcSEcCtD
Alitretinoin—Anaphylactic shock—Prednisone—systemic scleroderma	0.000114	0.000219	CcSEcCtD
Alitretinoin—Infection—Prednisone—systemic scleroderma	0.000113	0.000217	CcSEcCtD
Alitretinoin—Back pain—Methotrexate—systemic scleroderma	0.000112	0.000217	CcSEcCtD
Alitretinoin—Shock—Prednisone—systemic scleroderma	0.000112	0.000215	CcSEcCtD
Alitretinoin—Nervous system disorder—Prednisone—systemic scleroderma	0.000111	0.000214	CcSEcCtD
Alitretinoin—Tachycardia—Prednisone—systemic scleroderma	0.000111	0.000213	CcSEcCtD
Alitretinoin—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000111	0.000213	CcSEcCtD
Alitretinoin—Skin disorder—Prednisone—systemic scleroderma	0.00011	0.000212	CcSEcCtD
Alitretinoin—Hyperhidrosis—Prednisone—systemic scleroderma	0.00011	0.000211	CcSEcCtD
Alitretinoin—Vision blurred—Methotrexate—systemic scleroderma	0.00011	0.000211	CcSEcCtD
Alitretinoin—Anorexia—Prednisone—systemic scleroderma	0.000108	0.000208	CcSEcCtD
Alitretinoin—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000108	0.000208	CcSEcCtD
Alitretinoin—Anaemia—Methotrexate—systemic scleroderma	0.000107	0.000207	CcSEcCtD
Alitretinoin—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000205	CcSEcCtD
Alitretinoin—Rash—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000203	CcSEcCtD
Alitretinoin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000203	CcSEcCtD
Alitretinoin—Headache—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000202	CcSEcCtD
Alitretinoin—Malaise—Methotrexate—systemic scleroderma	0.000105	0.000202	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000103	0.000199	CcSEcCtD
Alitretinoin—Insomnia—Prednisone—systemic scleroderma	0.000103	0.000198	CcSEcCtD
Alitretinoin—Paraesthesia—Prednisone—systemic scleroderma	0.000102	0.000196	CcSEcCtD
Alitretinoin—Cough—Methotrexate—systemic scleroderma	0.000101	0.000195	CcSEcCtD
Alitretinoin—Convulsion—Methotrexate—systemic scleroderma	0.000101	0.000194	CcSEcCtD
Alitretinoin—Dyspepsia—Prednisone—systemic scleroderma	9.99e-05	0.000192	CcSEcCtD
Alitretinoin—Nausea—Mycophenolate mofetil—systemic scleroderma	9.95e-05	0.000192	CcSEcCtD
Alitretinoin—Myalgia—Methotrexate—systemic scleroderma	9.9e-05	0.000191	CcSEcCtD
Alitretinoin—Chest pain—Methotrexate—systemic scleroderma	9.9e-05	0.000191	CcSEcCtD
Alitretinoin—Arthralgia—Methotrexate—systemic scleroderma	9.9e-05	0.000191	CcSEcCtD
Alitretinoin—Decreased appetite—Prednisone—systemic scleroderma	9.87e-05	0.00019	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	9.83e-05	0.000189	CcSEcCtD
Alitretinoin—Fatigue—Prednisone—systemic scleroderma	9.79e-05	0.000188	CcSEcCtD
Alitretinoin—Discomfort—Methotrexate—systemic scleroderma	9.78e-05	0.000188	CcSEcCtD
Alitretinoin—Constipation—Prednisone—systemic scleroderma	9.71e-05	0.000187	CcSEcCtD
Alitretinoin—Confusional state—Methotrexate—systemic scleroderma	9.57e-05	0.000184	CcSEcCtD
Alitretinoin—Anaphylactic shock—Methotrexate—systemic scleroderma	9.49e-05	0.000183	CcSEcCtD
Alitretinoin—Infection—Methotrexate—systemic scleroderma	9.43e-05	0.000181	CcSEcCtD
Alitretinoin—Feeling abnormal—Prednisone—systemic scleroderma	9.36e-05	0.00018	CcSEcCtD
Alitretinoin—Nervous system disorder—Methotrexate—systemic scleroderma	9.3e-05	0.000179	CcSEcCtD
Alitretinoin—Thrombocytopenia—Methotrexate—systemic scleroderma	9.29e-05	0.000179	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Prednisone—systemic scleroderma	9.28e-05	0.000179	CcSEcCtD
Alitretinoin—Skin disorder—Methotrexate—systemic scleroderma	9.22e-05	0.000177	CcSEcCtD
Alitretinoin—Hyperhidrosis—Methotrexate—systemic scleroderma	9.17e-05	0.000177	CcSEcCtD
Alitretinoin—Anorexia—Methotrexate—systemic scleroderma	9.04e-05	0.000174	CcSEcCtD
Alitretinoin—Urticaria—Prednisone—systemic scleroderma	9.02e-05	0.000174	CcSEcCtD
Alitretinoin—Body temperature increased—Prednisone—systemic scleroderma	8.97e-05	0.000173	CcSEcCtD
Alitretinoin—Abdominal pain—Prednisone—systemic scleroderma	8.97e-05	0.000173	CcSEcCtD
Alitretinoin—Hypotension—Methotrexate—systemic scleroderma	8.87e-05	0.000171	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	8.64e-05	0.000166	CcSEcCtD
Alitretinoin—Insomnia—Methotrexate—systemic scleroderma	8.58e-05	0.000165	CcSEcCtD
Alitretinoin—Paraesthesia—Methotrexate—systemic scleroderma	8.52e-05	0.000164	CcSEcCtD
Alitretinoin—Dyspnoea—Methotrexate—systemic scleroderma	8.46e-05	0.000163	CcSEcCtD
Alitretinoin—Somnolence—Methotrexate—systemic scleroderma	8.44e-05	0.000162	CcSEcCtD
Alitretinoin—Hypersensitivity—Prednisone—systemic scleroderma	8.36e-05	0.000161	CcSEcCtD
Alitretinoin—Dyspepsia—Methotrexate—systemic scleroderma	8.35e-05	0.000161	CcSEcCtD
Alitretinoin—Decreased appetite—Methotrexate—systemic scleroderma	8.25e-05	0.000159	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	8.19e-05	0.000158	CcSEcCtD
Alitretinoin—Fatigue—Methotrexate—systemic scleroderma	8.18e-05	0.000158	CcSEcCtD
Alitretinoin—Asthenia—Prednisone—systemic scleroderma	8.15e-05	0.000157	CcSEcCtD
Alitretinoin—Pain—Methotrexate—systemic scleroderma	8.11e-05	0.000156	CcSEcCtD
Alitretinoin—Pruritus—Prednisone—systemic scleroderma	8.03e-05	0.000155	CcSEcCtD
Alitretinoin—Feeling abnormal—Methotrexate—systemic scleroderma	7.82e-05	0.000151	CcSEcCtD
Alitretinoin—Diarrhoea—Prednisone—systemic scleroderma	7.77e-05	0.00015	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Methotrexate—systemic scleroderma	7.76e-05	0.000149	CcSEcCtD
Alitretinoin—Urticaria—Methotrexate—systemic scleroderma	7.54e-05	0.000145	CcSEcCtD
Alitretinoin—Dizziness—Prednisone—systemic scleroderma	7.51e-05	0.000145	CcSEcCtD
Alitretinoin—Abdominal pain—Methotrexate—systemic scleroderma	7.5e-05	0.000144	CcSEcCtD
Alitretinoin—Body temperature increased—Methotrexate—systemic scleroderma	7.5e-05	0.000144	CcSEcCtD
Alitretinoin—Vomiting—Prednisone—systemic scleroderma	7.22e-05	0.000139	CcSEcCtD
Alitretinoin—Rash—Prednisone—systemic scleroderma	7.16e-05	0.000138	CcSEcCtD
Alitretinoin—Dermatitis—Prednisone—systemic scleroderma	7.15e-05	0.000138	CcSEcCtD
Alitretinoin—Headache—Prednisone—systemic scleroderma	7.11e-05	0.000137	CcSEcCtD
Alitretinoin—Hypersensitivity—Methotrexate—systemic scleroderma	6.99e-05	0.000135	CcSEcCtD
Alitretinoin—Asthenia—Methotrexate—systemic scleroderma	6.81e-05	0.000131	CcSEcCtD
Alitretinoin—Nausea—Prednisone—systemic scleroderma	6.74e-05	0.00013	CcSEcCtD
Alitretinoin—Pruritus—Methotrexate—systemic scleroderma	6.71e-05	0.000129	CcSEcCtD
Alitretinoin—Diarrhoea—Methotrexate—systemic scleroderma	6.49e-05	0.000125	CcSEcCtD
Alitretinoin—Dizziness—Methotrexate—systemic scleroderma	6.27e-05	0.000121	CcSEcCtD
Alitretinoin—Vomiting—Methotrexate—systemic scleroderma	6.03e-05	0.000116	CcSEcCtD
Alitretinoin—Rash—Methotrexate—systemic scleroderma	5.98e-05	0.000115	CcSEcCtD
Alitretinoin—Dermatitis—Methotrexate—systemic scleroderma	5.98e-05	0.000115	CcSEcCtD
Alitretinoin—Headache—Methotrexate—systemic scleroderma	5.94e-05	0.000114	CcSEcCtD
Alitretinoin—Nausea—Methotrexate—systemic scleroderma	5.64e-05	0.000109	CcSEcCtD
